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Introduction
Biomedical knowledge is growing exponentially; however, meta-knowledge around the data is 
often lacking. PubMed is a database comprising more than 21 million citations for biomedical 
literature from MEDLINE and additional life science journals dating back to the 1950s. To explore 
the use and frequency of biomarkers across human disease, we mined PubMed for biomarker-
disease associations. We then ranked the top 100 linked diseases by relevance and mapped 
them to medical subject headings (MeSH) and, subsequently, to the Disease Ontology. To identify 
biomarkers for each disease, we queried Covance BioPathways, an online data resource that 
maps commercial biomarker assays to biological and disease pathways. We then integrated 
pathways-based information to describe both known and potential biomarkers as well as disease-
associated genes/proteins for select diseases. This approach identifies therapeutic areas 
with candidate or validated biomarkers, and highlights those areas where a paucity of 
biomarkers exists.
Results
Data Extraction and Curation 
In June 2011, we mined PubMed for term (“biomarker”)-disease associations and identified a  
total of 1,181 disease associations (Table 1). We then curated the top 100 disease 
associations from the list, mapping each result to both medical subject (MeSH) ID and Disease 
Ontology ID (DOID), and then subsequently queried the GeneGo diseases ontology for 
associated biomarkers (Table 2). Of 100 results, 62 map to both MeSH ID and DOID and are 
shown below.
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Table 2. The curated list of disease associations minded from PubMed and organized by high-level 
Disease Ontology. Each specific disease association has a unique MeSH ID, DOID and number of 
associated genes as defined in the GeneGo MetaCore knowledgebase.
Materials and Methods
Text mining was performed using PolySearch, a web-based text mining system for extracting 
relationships between human diseases, genes, mutations, drugs and metabolites [Cheng et al., 
2008]. The MeSH Browser (2012 MeSH) was used to map disease associations to MeSH IDs. 
Once MeSH IDs were assigned, the Disease Ontology was used to map DOIDs [Schriml et al., 
2011]. Interaction networks were constructed in GeneGo MetaCore [Ekins et al., 2007] using 
the Auto expand algorithm, which gradually expands sub-networks around every object from the 
seed object list based on interactions identified in the literature. At every step, preference is 
given to objects with more connectivity to the initial object, and expansion halts when the 
sub-networks intersect, or when the overall network size reaches a predefined limit. Genes/
proteins for which validated commercial assays exist were identified using Covance 
BioPathways at http://www.Covance.com/BioPathways and are indicated with a red dot . 
These genes/proteins can be considered potential biomarkers.
Disease Interaction Network and Biomarker Assay Identification
For illustrative purposes, we constructed an interaction network around disease-associated 
genes for two diseases—one with few associated genes (atherosclerosis) and one with many 
associated genes (asthma)—using a network building algorithm in GeneGo MetaCore. For each 
interaction network gene set, we then queried Covance BioPathways, a publicly accessible, 
web-based data source that integrates biological and disease pathway maps with validated 
Covance assays and antibody products, to identify commercially available biomarker assays. 
Discussion
Given the molecular interdependencies within a cell, a disease is rarely a consequence of a 
single gene abnormality but instead reflects the perturbation of a complex network of biological 
and signaling pathways. The approach described here describes the detection and ranking of 
human disease based on research/clinical activity surrounding biomarkers. It also enables the 
identification of therapeutic areas with candidate or validated biomarkers. The strategy takes an 
integrative approach to identify candidate disease biomarkers by combining disease-associated 
genes/proteins with commercially validated assays for known biomarkers. We first constructed 
a system-level model of disease that incorporates molecular interactions across biological and 
signaling pathways. We then identified each gene/protein in the model that has an existing 
commercially validated assay. This research offers an alternative, comprehensive view of key 
relationships and pathway perturbations that may identify biomarkers of disease emergence 
or progression.
Table 1. A representative list of term (“biomarker”)-disease associations mined from PubMed in June 
2011. The top 100 disease associations were ranked by Z Score. The Z-score indicates the number 
of standard deviations that the relevancy score is above the mean; larger Z-scores denote stronger 
associations. The top 100 data set is available under the Open Data Commons Attribution License at 
http://BiomarkerCommons.org.
Figure 1. Atherosclerosis interaction network. Disease-associated genes are indicated with blue 
halos; genes without a halo were included by the network building algorithm. Biomarkers that have 
commercially validated assays are indicated with a red dot  ; they either are known or can be 
considered potential atherosclerosis biomarkers.
Figure 2. Asthma interaction network. All nodes shown are disease-associated genes. Biomarkers 
that have commercially validated assays are indicated with a red dot  ; they are either known or 
can be considered potential asthma biomarkers.
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